@Article{or.2023.028406,
AUTHOR = {EFFAT ALEMZADEH, LEILA ALLAHQOLI, HAMIDEH DEHGHAN, AFROOZ MAZIDIMORADI, ALIREZA GHASEMPOUR, HAMID SALEHINIYA},
TITLE = {Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring},
JOURNAL = {Oncology Research},
VOLUME = {31},
YEAR = {2023},
NUMBER = {5},
PAGES = {667--675},
URL = {http://www.techscience.com/or/v31n5/53697},
ISSN = {1555-3906},
ABSTRACT = {Liquid biopsy, including both circulating tumor cells and circulating tumor DNA, is becoming more popular as
a diagnostic tool in the clinical management of breast cancer. Elevated concentrations of these biomarkers during cancer
treatment may be used as markers for cancer progression as well as to understand the mechanisms underlying metastasis
and treatment resistance. Thus, these circulating markers serve as tools for cancer assessing and monitoring through a
simple, non-invasive blood draw. However, despite several study results currently noting a potential clinical impact of
ctDNA mutation tracking, the method is not used clinically in cancer diagnosis among patients and more studies are
required to confirm it. This review focuses on understanding circulating tumor biomarkers, especially in breast cancer.},
DOI = {10.32604/or.2023.028406}
}